Single- Versus Multiple-sampling Strategy for Blood Cultures in the Diagnosis of Infective Endocarditis: The Prospective Multicenter UniEndo Study
- PMID: 40176205
- DOI: 10.1093/cid/ciaf163
Single- Versus Multiple-sampling Strategy for Blood Cultures in the Diagnosis of Infective Endocarditis: The Prospective Multicenter UniEndo Study
Abstract
Background: Single-sampling strategy (SSS) for blood cultures (BCs) has not been evaluated in infective endocarditis (IE). We assessed the diagnostic performance of SSS versus conventional multisampling strategy (MSS) in IE diagnosis.
Methods: Patients suspected of IE were prospectively enrolled in 8 tertiary-care centers. Five BC bottle pairs were sampled from each patient. Pairs 1, 2, and 3 were sampled simultaneously, followed by 2 additional separate pairs (4 and 5) sampled more than 1 hour later. Pairs 1, 2, and 3 emulated SSS and pairs 1, 4, and 5 emulated MSS. The sensitivity and specificity of the major microbiologic criterion of the 2015 European Society of Cardiology IE diagnostic criteria, based on the SSS and MSS BC results, were calculated using the endocarditis team's diagnosis as the gold standard.
Results: An IE was diagnosed in 101 (39.4%) of the 256 patients enrolled. Sensitivity rates of SSS and MSS were 50.5% (95% CI: 40.7-60.2) and 45.5% (95% CI: 35.8-55.3), respectively (P = .063), whereas specificity rates were 94.8% (95% CI: 91.4-98.3) and 95.5% (95% CI: 92.2-98.8), respectively (P = 1). In IE patients, SSS compared to MSS accurately upgraded the diagnosis from possible to definite IE in 1 patient and downgraded it in none.
Conclusions: Using SSS to define the major microbiologic criterion was as sensitive and specific as using MSS for diagnosing IE. Using SSS instead of MSS BC results did not lead to erroneous changes in diagnostic class according to the 2015 European Society of Cardiology criteria. Consequently, SSS may be regarded as standard practice for IE diagnosis.
Keywords: blood culture; blood sampling; diagnostic strategy; infective endocarditis; prospective study.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest . V. L. M. disclosed consulting fees, payment for lecture and support for attending meeting from Pfizer laboratory, and payment for lectures from Advanz Pharma laboratory. All the other coauthors have nothing to declare. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

